With a market capitalization (market cap) of $26.46B — a measure of how much the company is worth — Royalty Pharma plc is the 517th most valuable company in Healthcare as of August 18, 2026. Shares trade at $59.69, up +0.40% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Visit websiteAs of August 18, 2026, Royalty Pharma plc (RPRX) is worth $26.46B — this is its market capitalization, the total value of all its outstanding shares.
Royalty Pharma plc’s market cap is $26.46B, which ranks it #517 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Royalty Pharma plc (RPRX) shares trade at $59.69, up 0.40% on the day, as of August 18, 2026.
Royalty Pharma plc trades at a price-to-earnings (P/E) ratio of 25.6, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025